Search
Cyclophosphamide Treatment Options in United Kingdom
A collection of 244 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United Kingdom . Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
49 - 60 of 244
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
Active Not Recruiting
International, randomised, open label, neo-adjuvant phase II trial in women with newly diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims to evaluate the effects of adding ipatasertib to chemotherapy and atezolizumab in patients with and without PI3CA/AKT1/PTEN genetic alterations.
International, randomised, open label, neo-adjuvant phase II trial in women with newly diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims to evaluate the effects of adding ipatasertib to chemotherapy and atezolizumab in patients with and without PI3CA/AKT1/PTEN genetic alterations. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: Barts Health NHS Trust, London, Not set
Barts Health NHS Trust, London, Not set
Conditions: Triple Negative Breast Cancer
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
Completed
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab. Read Less
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/04/2025
Locations: Clinical Trial Site, Huntsville, Alabama +197 locations
Clinical Trial Site, Huntsville, Alabama
Clinical Trial Site, Phoenix, Arizona
Clinical Trial Site, Phoenix, Arizona
Clinical Trial Site, Los Angeles, California
Clinical Trial Site, Santa Monica, California
Clinical Trial Site, Aurora, Colorado
Clinical Trial Site, Washington, District of Columbia
Clinical Trial Site, Daytona Beach, Florida
Clinical Trial Site, Tampa, Florida
Clinical Trial Site, Atlanta, Georgia
Clinical Trial Site, Meridian, Idaho
Clinical Trial Site, Chicago, Illinois
Clinical Trial Site, Indianapolis, Indiana
Clinical Trial Site, Kansas City, Kansas
Clinical Trial Site, Lexington, Kentucky
Clinical Trial Site, Shreveport, Louisiana
Clinical Trial Site, Baltimore, Maryland
Clinical Trial Site, Boston, Massachusetts
Clinical Trial Site, Boston, Massachusetts
Clinical Trial Site, Ann Arbor, Michigan
Clinical Trial Site, Minneapolis, Minnesota
Clinical Trial Site, Rochester, Minnesota
Clinical Trial Site, Saint Louis, Missouri
Clinical Trial Site, Great Neck, New York
Clinical Trial Site, Mineola, New York
Clinical Trial Site, New York, New York
Clinical Trial Site, New York, New York
Clinical Trial Site, Chapel Hill, North Carolina
Clinical Trial Site, Greenville, North Carolina
Clinical Trial Site, Winston-Salem, North Carolina
Clinical Trial Site, Cleveland, Ohio
Clinical Trial Site, Columbus, Ohio
Clinical Trial Site, Duncansville, Pennsylvania
Clinical Trial Site, Philadelphia, Pennsylvania
Clinical Trial Site, Pittsburgh, Pennsylvania
Clinical Trial Site, Providence, Rhode Island
Clinical Trial Site, Charleston, South Carolina
Clinical Trial Site, Dallas, Texas
Clinical Trial Site, Houston, Texas
Clinical Trial Site, Salt Lake City, Utah
Clinical Trial Site, Seattle, Washington
Clinical Trial Site, Adelaide, Not set
Clinical Trial Site, Auchenflower, Not set
Clinical Trial Site, Brisbane, Not set
Clinical Trial Site, Clayton, Not set
Clinical Trial Site, Concord, Not set
Clinical Trial Site, Heidelberg, Not set
Clinical Trial Site, Liverpool, Not set
Clinical Trial Site, Nambour, Not set
Clinical Trial Site, Nedlands, Not set
Clinical Trial Site, Randwick, Not set
Clinical Trial Site, Saint Albans, Not set
Clinical Trial Site, Southport, Not set
Clinical Trial Site, St Leonards, Not set
Clinical Trial Site, Westmead, Not set
Clinical Trial Site, Woolloongabba, Not set
Clinical Trial Site, Feldkirch, Not set
Clinical Trial Site, Graz, Not set
Clinical Trial Site, Innsbruck, Not set
Clinical Trial Site, Antwerp, Not set
Clinical Trial Site, Brussels, Not set
Clinical Trial Site, Leuven, Not set
Clinical Trial Site, Liège, Not set
Clinical Trial Site, Calgary, Not set
Clinical Trial Site, Greenfield Park, Not set
Clinical Trial Site, Hamilton, Not set
Clinical Trial Site, Montréal, Not set
Clinical Trial Site, Québec, Not set
Clinical Trial Site, Sherbrooke, Not set
Clinical Trial Site, Toronto, Not set
Clinical Trial Site, Vancouver, Not set
Clinical Trial Site, Olomouc, Not set
Clinical Trial Site, Praha, Not set
Clinical Trial Site, Aalborg, Not set
Clinical Trial Site, Aarhus, Not set
Clinical Trial Site, Copenhagen, Not set
Clinical Trial Site, Odense, Not set
Clinical Trial Site, Roskilde, Not set
Clinical Trial Site, Angers, Not set
Clinical Trial Site, Bordeaux, Not set
Clinical Trial Site, Boulogne-sur-Mer, Not set
Clinical Trial Site, Brest, Not set
Clinical Trial Site, Bron, Not set
Clinical Trial Site, Caen, Not set
Clinical Trial Site, Colmar, Not set
Clinical Trial Site, Grenoble, Not set
Clinical Trial Site, Marseille, Not set
Clinical Trial Site, Metz, Not set
Clinical Trial Site, Nantes, Not set
Clinical Trial Site, Nîmes, Not set
Clinical Trial Site, Paris, Not set
Clinical Trial Site, Toulouse, Not set
Clinical Trial Site, Valenciennes, Not set
Clinical Trial Site, Aachen, Not set
Clinical Trial Site, Bad Bramstedt, Not set
Clinical Trial Site, Berlin, Not set
Clinical Trial Site, Cologne, Not set
Clinical Trial Site, Dresden, Not set
Clinical Trial Site, Essen, Not set
Clinical Trial Site, Freiburg, Not set
Clinical Trial Site, Fulda, Not set
Clinical Trial Site, Hamburg, Not set
Clinical Trial Site, Hannover, Not set
Clinical Trial Site, Heidelberg, Not set
Clinical Trial Site, Jena, Not set
Clinical Trial Site, Kirchheim unter Teck, Not set
Clinical Trial Site, Leipzig, Not set
Clinical Trial Site, Ludwigshafen, Not set
Clinical Trial Site, Lübeck, Not set
Clinical Trial Site, Mannheim, Not set
Clinical Trial Site, Munich, Not set
Clinical Trial Site, Tuebingen, Not set
Clinical Trial Site, Villingen-Schwenningen, Not set
Clinical Trial Site, Budapest, Not set
Clinical Trial Site, Debrecen, Not set
Clinical Trial Site, Cork, Not set
Clinical Trial Site, Dublin, Not set
Clinical Trial Site, Ancona, Not set
Clinical Trial Site, Firenze, Not set
Clinical Trial Site, Genova, Not set
Clinical Trial Site, Milano, Not set
Clinical Trial Site, Monza, Not set
Clinical Trial Site, Parma, Not set
Clinical Trial Site, Reggio Emilia, Not set
Clinical Trial Site, Torino, Not set
Clinical Trial Site, Udine, Not set
Clinical Trial Site, Aichi, Not set
Clinical Trial Site, Akita, Not set
Clinical Trial Site, Chiba, Not set
Clinical Trial Site, Hiroshima, Not set
Clinical Trial Site, Hokkaido, Not set
Clinical Trial Site, Ishikawa, Not set
Clinical Trial Site, Kagawa, Not set
Clinical Trial Site, Kanagawa, Not set
Clinical Trial Site, Kobe, Not set
Clinical Trial Site, Miyazaki, Not set
Clinical Trial Site, Nagoya, Not set
Clinical Trial Site, Okayama, Not set
Clinical Trial Site, Osaka, Not set
Clinical Trial Site, Saitama, Not set
Clinical Trial Site, Shimane, Not set
Clinical Trial Site, Shizuoka, Not set
Clinical Trial Site, Tokyo, Not set
Clinical Trial Site, Toyama, Not set
Clinical Trial Site, Yokohama, Not set
Clinical Trial Site, Groningen, Not set
Clinical Trial Site, Leiden, Not set
Clinical Trial Site, Rotterdam, Not set
Clinical Trial Site, Christchurch, Not set
Clinical Trial Site, Dunedin, Not set
Clinical Trial Site, Grafton, Not set
Clinical Trial Site, Hamilton, Not set
Clinical Trial Site, Takapuna, Not set
Clinical Trial Site, Nordbyhagen, Not set
Clinical Trial Site, Oslo, Not set
Clinical Trial Site, Tromsø, Not set
Clinical Trial Site, Badalona, Not set
Clinical Trial Site, Barcelona, Not set
Clinical Trial Site, Burela, Not set
Clinical Trial Site, Lleida, Not set
Clinical Trial Site, Madrid, Not set
Clinical Trial Site, San Sebastián, Not set
Clinical Trial Site, Linköping, Not set
Clinical Trial Site, Lund, Not set
Clinical Trial Site, Stockholm, Not set
Clinical Trial Site, Uppsala, Not set
Clinical Trial Site, Örebro, Not set
Clinical Trial Site, Basel, Not set
Clinical Trial Site, Bern, Not set
Clinical Trial Site, Fribourg, Not set
Clinical Trial Site, Lausanne, Not set
Clinical Trial Site, St. Gallen, Not set
Clinical Trial Site, Zürich, Not set
Clinical Trial Site, Aberdeen, Not set
Clinical Trial Site, Basildon, Not set
Clinical Trial Site, Birmingham, Not set
Clinical Trial Site, Bristol, Not set
Clinical Trial Site, Cambridge, Not set
Clinical Trial Site, Canterbury, Not set
Clinical Trial Site, Cardiff, Not set
Clinical Trial Site, Carshalton, Not set
Clinical Trial Site, Dorchester, Not set
Clinical Trial Site, Dudley, Not set
Clinical Trial Site, Exeter, Not set
Clinical Trial Site, Glasgow, Not set
Clinical Trial Site, Inverness, Not set
Clinical Trial Site, Kirkcaldy, Not set
Clinical Trial Site, Leeds, Not set
Clinical Trial Site, Leicester, Not set
Clinical Trial Site, Liverpool, Not set
Clinical Trial Site, London, Not set
Clinical Trial Site, Manchester, Not set
Clinical Trial Site, Newcastle, Not set
Clinical Trial Site, Nottingham, Not set
Clinical Trial Site, Oxford, Not set
Clinical Trial Site, Reading, Not set
Clinical Trial Site, Salford, Not set
Clinical Trial Site, Westcliff-on-Sea, Not set
Conditions: ANCA-Associated Vasculitis
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Completed
The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene expression profiling (GEP) or both populations.
The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene expression profiling (GEP) or both populations. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Not set, Tucson, Arizona +204 locations
Not set, Tucson, Arizona
Not set, Greenbrae, California
Not set, La Jolla, California
Not set, Los Angeles, California
Not set, Salinas, California
Not set, Stanford, California
Not set, Danbury, Connecticut
Not set, Hartford, Connecticut
Not set, Washington, District of Columbia
Not set, Atlanta, Georgia
Not set, Marietta, Georgia
Not set, Peoria, Illinois
Not set, Fort Wayne, Indiana
Not set, Goshen, Indiana
Not set, Indianapolis, Indiana
Not set, Topeka, Kansas
Not set, Louisville, Kentucky
Not set, Baton Rouge, Louisiana
Not set, New Orleans, Louisiana
Not set, Baltimore, Maryland
Not set, Bethesda, Maryland
Not set, Boston, Massachusetts
Not set, Ann Arbor, Michigan
Not set, Saint Louis, Missouri
Not set, Omaha, Nebraska
Not set, Hackensack, New Jersey
Not set, New Brunswick, New Jersey
Not set, Bronx, New York
Not set, Fresh Meadows, New York
Not set, Johnson City, New York
Not set, Mineola, New York
Not set, New York, New York
Not set, Rochester, New York
Not set, Charlotte, North Carolina
Not set, Greenville, North Carolina
Not set, Hickory, North Carolina
Not set, Columbus, Ohio
Not set, Portland, Oregon
Not set, North Charleston, South Carolina
Not set, Nashville, Tennessee
Not set, Houston, Texas
Not set, Temple, Texas
Not set, Burlington, Vermont
Not set, Seattle, Washington
Not set, Buenos Aires, Not set
Not set, Ciudad Autonoma de Buenos Aires, Not set
Not set, Ciudad de Buenos Aires, Not set
Not set, Adelaide, Not set
Not set, Concord, Not set
Not set, Darlinghurst, Not set
Not set, Hobart, Not set
Not set, Melbourne, Not set
Not set, Nedlands, Not set
Not set, Perth, Not set
Not set, Randwick, Not set
Not set, South Brisbane, Not set
Not set, Woolloongabba, Not set
Not set, Antwerpen, Not set
Not set, Brugge, Not set
Not set, Brussel, Not set
Not set, Gent, Not set
Not set, Haine Saint Paul La Louviere, Not set
Not set, Kortrijk, Not set
Not set, Leuven, Not set
Not set, Porto Alegre, Not set
Not set, Rio De Janeiro, Not set
Not set, Sao Paulo, Not set
Not set, Edmonton, Alberta
Not set, Vancouver, British Columbia
Not set, Halifax, Nova Scotia
Not set, Toronto, Ontario
Not set, Levis, Quebec
Not set, Montreal, Quebec
Not set, Montréal, Quebec
Not set, Beijing, Not set
Not set, Changchun, Not set
Not set, Chengdu, Not set
Not set, Guangzhou, Not set
Not set, Hangzhou, Not set
Not set, Harbin, Not set
Not set, Jinan, Not set
Not set, Nanjing, Not set
Not set, Shanghai, Not set
Not set, Tianjin, Not set
Not set, Brno, Not set
Not set, Hradec Kralove, Not set
Not set, Ostrava, Not set
Not set, Praha 10, Not set
Not set, Praha 2, Not set
Not set, Aarhus N., Not set
Not set, Copenhagen, Not set
Not set, Roskilde, Not set
Not set, Vejle, Not set
Not set, Helsinki, Not set
Not set, Jyväskylä, Not set
Not set, Oulu, Not set
Not set, Turku, Not set
Not set, Grenoble Cedex 9, Not set
Not set, Limoges, Not set
Not set, Paris, Not set
Not set, Pessac, Not set
Not set, Pierre Benite, Not set
Not set, Rouen, Not set
Not set, Tours, Not set
Not set, Villejuif, Not set
Not set, Augsburg, Not set
Not set, Bamberg, Not set
Not set, Berlin, Not set
Not set, Dresden, Not set
Not set, Essen, Not set
Not set, Frankfurt, Not set
Not set, Jena, Not set
Not set, Muenchen, Not set
Not set, Münster, Not set
Not set, Villingen-Schwenningen, Not set
Not set, Budapest N/a, Not set
Not set, Debrecen, Not set
Not set, Gyula, Not set
Not set, Szombathely, Not set
Not set, Veszprém, Not set
Not set, Beer-Sheva, Not set
Not set, Hadera, Not set
Not set, Haifa, Not set
Not set, Petah Tikva, Not set
Not set, Ramat-Gan, Not set
Not set, Tel Aviv, Not set
Not set, Fukuoka, Not set
Not set, Hiroshima, Not set
Not set, Isehara, Not set
Not set, Kobe, Not set
Not set, Kumamoto, Not set
Not set, Kyoto, Not set
Not set, Nagano, Not set
Not set, Nagoya, Not set
Not set, Narita, Not set
Not set, Osaka-Sayama, Not set
Not set, Osaka, Not set
Not set, Sapporo, Not set
Not set, Sendai-shi, Not set
Not set, Suita, Not set
Not set, Tachikawa, Not set
Not set, Tokyo, Not set
Not set, Tsukuba, Not set
Not set, Busan, Not set
Not set, Goyang-Si, Not set
Not set, Seoul, Not set
Not set, Mexico, Not set
Not set, Monterrey, Not set
Not set, San Luis Potosi, Not set
Not set, Amsterdam Zuidoost, Not set
Not set, Arnhem, Not set
Not set, Dordrecht, Not set
Not set, Groningen, Not set
Not set, Leiden, Not set
Not set, Nieuwegein, Not set
Not set, Rotterdam, Not set
Not set, Oslo, Not set
Not set, Tromso, Not set
Not set, Brzozow, Not set
Not set, Chorzow, Not set
Not set, Krakow, Not set
Not set, Lodz, Not set
Not set, Olsztyn, Not set
Not set, Poznan, Not set
Not set, Warszawa, Not set
Not set, Wroclaw, Not set
Not set, Ekaterinburg, Not set
Not set, Moscow, Not set
Not set, Nizhny Novgorod, Not set
Not set, Rostov-Na-Donu, Not set
Not set, Saint-Petersburg, Not set
Not set, Sochi, Not set
Not set, St. Petersburg, Not set
Not set, Volgograd, Not set
Not set, Barcelona, Not set
Not set, Madrid, Not set
Not set, Salamanca, Not set
Not set, Sevilla, Not set
Not set, Linköping, Not set
Not set, Luleå, Not set
Not set, Lund, Not set
Not set, Uppsala, Not set
Not set, Taichung, Not set
Not set, Tainan, Not set
Not set, Taoyuan County, Not set
Not set, Adana, Not set
Not set, Ankara, Not set
Not set, Istanbul, Not set
Not set, Izmir, Not set
Not set, Kayseri, Not set
Not set, Samsun, Not set
Not set, Cherkassy, Not set
Not set, Khmelnitskiy, Not set
Not set, Kiev, Not set
Not set, Lviv, Not set
Not set, Makiivka, Not set
Not set, Glasgow, Not set
Not set, Liverpool, Not set
Not set, London, Not set
Not set, Maidstone, Not set
Not set, Manchester, Not set
Not set, Nottingham, Not set
Not set, Oxford, Not set
Not set, Romford, Not set
Not set, Southampton, Not set
Conditions: Lymphoma
Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)
Completed
The OMS/DES study is a multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome.
This trial brought on the way by specialists of the EPNS (European Paediatric Neurology Society), the GPOH (Gesellschaft für Pädiatrische Hematologic und Oncologie) and the SIOPEN (SIOP (International Society Oncology Pediatric) Europe Neuroblastoma).
This protocol will investigate an escalating treatment schedule starting with a corticosteroid standard treatment with... Read More
The OMS/DES study is a multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome.
This trial brought on the way by specialists of the EPNS (European Paediatric Neurology Society), the GPOH (Gesellschaft für Pädiatrische Hematologic und Oncologie) and the SIOPEN (SIOP (International Society Oncology Pediatric) Europe Neuroblastoma).
This protocol will investigate an escalating treatment schedule starting with a corticosteroid standard treatment with dexamethasone pulses (first step), which is followed, if response has been inadequate after 3 months of treatment, by the addition of CP (second step) and, if still no sufficient improvement, by the replacement of CP by Rituximab (third step). Treatment intensification is decided on the basis of standardized scoring of OMS/DES severity. Read Less
Gender:
ALL
Ages:
Between 6 months and 8 years
Trial Updated:
01/31/2025
Locations: St. Anna Kinderkrebsforschung e.V. CHILDREN'S CANCER RESEARCH INSTITUTE, Wien, Not set +35 locations
St. Anna Kinderkrebsforschung e.V. CHILDREN'S CANCER RESEARCH INSTITUTE, Wien, Not set
Chu de Bicetre, Le Kremlin-Bicêtre, LE Kremlin Bicetre
Centre Oscar Lambret, Lille, Lille Cedex
Centre Leon Berard, Lyon, LYON Cedex 08
Hopita D'Enfants de La Timone, Marseille, Marseille Cedex 5
Hopital Arnaud de Villeneuve, Montpellier, Montpellier Cedex 4
Chr de Nantes, Nantes, Nantes Cedex01
Chu de Nice Archet 2, Nice, NICE Cedex 03
Ch Trousseau, Paris, Paris Cedex 12
Chu Hopital Sud, Rennes, Rennes Cedex 02
Chu de Rouen, Rouen, Rouen Cedex
CHU DE STRASBOURG HOPITAL Hautepierre, Strasbourg, Strasbourg Cedex
Chu Toulouse Hopital Des Enfants, Toulouse, Toulouse Cedex 9
Chu Amiens, Amiens, Not set
Chu Angers, Angers, Not set
Hopital Jean Minjoz, Besancon, Not set
Chr Pellegrin, Bordeaux, Not set
CHU CAEN, Caen, Not set
Chu D'Estaing, Clermont Ferrand, Not set
Chu Dijon, Dijon, Not set
Chu de Grenoble, Grenoble, Not set
Chu de Limoges, Limoges, Not set
Institut Curie, Paris, Not set
Chu de Poitiers, Poitiers, Not set
Chu de Reims, Reims, Not set
CHU LA REUNION Site Félix Guyon, Saint-denis, Not set
Chu Saint Etienne, Saint-Étienne, Not set
Chu Tours Hopital Clocheville, Tours, Not set
Hopital Nancy Brabois, Vandoeuvre Les Nancy, Not set
Institut de Cancerologie Gustave Roussy, Villejuif, Not set
G. Gaslini Institut, Genova, Not set
The Fundación para la Formación e Investigación Sanitarias de la Región de Murcia, El Palmar, Not set
University Hospital Lund, Lund, Not set
Universitätskinderklinik, Bern, Not set
Kinderspital Zurich, Zurich, Not set
John Radcliffe Hospital, Oxford, Not set
Conditions: Opsoclonus Myoclonus Syndrome, Neuroblastoma
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Active Not Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed.
Epcoritamab is an... Read More
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed by epcoritamab or R-CHOP followed by rituximab will be explored. Approximately 900 adult participants with with newly diagnosed DLBCL will be enrolled in the study in approximately 315 sites in globally.
In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects. Read Less
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
01/22/2025
Locations: University of Arizona Cancer Center - North Campus /ID# 227463, Tucson, Arizona +330 locations
University of Arizona Cancer Center - North Campus /ID# 227463, Tucson, Arizona
Yuma Regional Medical Center /ID# 261527, Yuma, Arizona
University of Arkansas for Medical Sciences /ID# 225703, Little Rock, Arkansas
CBCC Global Research, Inc. /ID# 262037, Bakersfield, California
Alta Bates Summit Medical Center for Research /ID# 229427, Berkeley, California
Orange Coast Memorial Medical Center /ID# 229632, Fountain Valley, California
Providence - St. Jude Medical Center /ID# 262042, Fullerton, California
Saddleback Memorial Medical Center /ID# 229631, Laguna Hills, California
Long Beach Memorial Medical Ct /ID# 228996, Long Beach, California
Cancer and Blood Speciality Clinic - Los Alamitos /ID# 262032, Los Alamitos, California
University of Southern California /ID# 225443, Los Angeles, California
University of California, Los Angeles /ID# 226887, Los Angeles, California
Kaiser Permanente, Waterpark III Institute for Health Research /ID# 228618, Aurora, Colorado
Cancer Specialists of North Florida /ID# 226826, Jacksonville, Florida
Ocala Oncology Florida Cancer Affiliates - Main /ID# 262785, Ocala, Florida
Orlando Health Cancer Institute /ID# 232626, Orlando, Florida
Straub Medical Center /ID# 229464, Honolulu, Hawaii
University of Illinois at Chicago /ID# 226889, Chicago, Illinois
Southern IL Univ School of Med /ID# 228999, Springfield, Illinois
Springfield Clinic Main Campus /ID# 262584, Springfield, Illinois
Carle Cancer Institute /ID# 228338, Urbana, Illinois
Parkview Comprehensive Cancer Center /ID# 227026, Fort Wayne, Indiana
Goshen Center for Cancer Care /ID# 225534, Goshen, Indiana
University of Iowa Health Care /ID# 261945, Des Moines, Iowa
Cancer Center of Kansas /ID# 261983, Wichita, Kansas
Norton Cancer Institute - St. Matthews /ID# 225420, Louisville, Kentucky
University of Maryland, Baltimore /ID# 225421, Baltimore, Maryland
Johns Hopkins Hospital /ID# 225369, Baltimore, Maryland
American Oncology Partners of Maryland /ID# 226859, Bethesda, Maryland
UMass Memorial Medical Center /ID# 226939, Worcester, Massachusetts
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 225462, Ann Arbor, Michigan
Trinity Health St. Joseph Mercy Ann Arbor /ID# 228206, Ypsilanti, Michigan
Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 226680, Saint Louis Park, Minnesota
University of Mississippi Medical Center /ID# 228045, Jackson, Mississippi
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 259014, Billings, Montana
NHO Revive Research Institute, LLC /ID# 261113, Lincoln, Nebraska
MDACC Cooper /ID# 260320, Camden, New Jersey
Titan Health Partners LLC, d/b/a Astera Cancer Care /ID# 226654, East Brunswick, New Jersey
Morristown Medical Center /ID# 239457, Morristown, New Jersey
University of New Mexico /ID# 227332, Albuquerque, New Mexico
Presbyterian Kaseman Hospital /ID# 262084, Albuquerque, New Mexico
Presbyterian Rust Medical Center /ID# 262068, Rio Rancho, New Mexico
New York Cancer and Blood Specialists- Eastchester, Bronx /ID# 265396, Bronx, New York
Roswell Park Cancer Institute /ID# 239127, Buffalo, New York
NYU Langone Hospital - Long Island /ID# 262412, Mineola, New York
New York Cancer and Blood Specialists- New Hyde Park /ID# 265392, New Hyde Park, New York
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 226141, New York, New York
New York Cancer and Blood Specialists- Manhattan /ID# 265391, New York, New York
Icahn School of Medicine at Mount Sinai /ID# 225370, New York, New York
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 225379, New York, New York
New York Cancer and Blood Specialists /ID# 261114, Port Jefferson Station, New York
Novant Health Presbyterian Medical Center /ID# 227753, Charlotte, North Carolina
East Carolina University - Brody School of Medicine /ID# 225992, Greenville, North Carolina
Novant Health Forsyth Medical Center /ID# 228339, Winston-Salem, North Carolina
University of Cincinnati /ID# 225374, Cincinnati, Ohio
OhioHealth Arthur G.H. Bing, MD Cancer Center /ID# 260790, Columbus, Ohio
University of Oklahoma, Stephenson Cancer Center /ID# 225556, Oklahoma City, Oklahoma
Kaiser Permanente - Northwest /ID# 225488, Portland, Oregon
Houston Methodist Hospital /ID# 258957, Houston, Texas
Millennium Research & Clinical Development /ID# 228284, Kingwood, Texas
Joe Arrington Cancer Research /ID# 227217, Lubbock, Texas
Baylor Scott & White Medical Center- Temple /ID# 225935, Temple, Texas
Intermountain Medical Center /ID# 231184, Murray, Utah
University of Virginia Cancer Center - West Complex /ID# 225433, Charlottesville, Virginia
Virginia Commonwealth University Medical Center Main Hospital /ID# 225796, Richmond, Virginia
Vista Oncology - East Olympia /ID# 229375, Olympia, Washington
MultiCare Institute for Research & Innovation /ID# 225432, Tacoma, Washington
MultiCare Regional Cancer Center - Tacoma /ID# 265285, Tacoma, Washington
Liverpool Hospital /ID# 230072, Liverpool, New South Wales
Royal Adelaide Hospital /ID# 225683, Adelaide, South Australia
Monash Health - Monash Medical Centre /ID# 225680, Clayton, Victoria
Austin Health /ID# 225716, Heidelberg, Victoria
The Alfred Hospital /ID# 225999, Melbourne, Victoria
Hollywood Private Hospital /ID# 251837, Nedlands, Western Australia
Perth Blood Institute Ltd /ID# 225679, Nedlands, Western Australia
Royal Perth Hospital /ID# 226583, Perth, Western Australia
Universitaetsklinikum St. Poelten /ID# 234016, Sankt Poelten, Niederoesterreich
Medizinische Universitaet Wien /ID# 252095, Vienna, Wien
Klinik Ottakring /ID# 243941, Vienna, Wien
Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 228360, Salzburg, Not set
Duplicate_ZAS Middelheim /ID# 225741, Antwerp, Antwerpen
ZAS Cadix /ID# 264327, Antwerp, Antwerpen
Cliniques Universitaires UCL Saint-Luc /ID# 225737, Woluwe-Saint-Lambert, Bruxelles-Capitale
Hospital La Louviere Site Jolimont - Helora /ID# 225738, La Louvière, Hainaut
CHU de Liège /ID# 225952, Liège, Liege
Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 225742, Yvoir, Namur
UZ Gent /ID# 250031, Gent, Oost-Vlaanderen
Vitaz /Id# 226153, Sint-Niklaas, Oost-Vlaanderen
Universitair Ziekenhuis Leuven /ID# 225951, Leuven, Vlaams-Brabant
AZ-Delta /ID# 225736, Roeselare, West-Vlaanderen
Institut Jules Bordet /ID# 225954, Anderlecht, Not set
AZ Sint-Jan Brugge /ID# 225735, Brugge, Not set
Hospital de Clinicas da Universidade Federal do Parana /ID# 226027, Curitiba, Parana
Hospital Amaral Carvalho - Fundacao Doutor Amaral Carvalho /ID# 226065, Jaú, Sao Paulo
Fundacao Antonio Prudente - AC Camargo Cancer Center /ID# 226809, São Paulo, Sao Paulo
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 252832, São Paulo, Sao Paulo
Instituto Nacional de Cancer (INCA) /ID# 226026, Rio de Janeiro, Not set
Real e Benemérita Associação Portuguesa de Beneficência /ID# 226023, Sao Paulo, Not set
Hospital Alemao Oswaldo Cruz /ID# 252833, Sao Paulo, Not set
Instituto D'Or de Pesquisa e Ensino - Regional Sao Paulo /ID# 262394, Sao Paulo, Not set
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 226048, Sao Paulo, Not set
UMHAT Sveti Georgi /ID# 245780, Plovdiv, Not set
Acibadem City Clinic Tokuda University Hospital EAD /ID# 244616, Sofia, Not set
UMHAT Sveti Ivan Rilski /ID# 244615, Sofia, Not set
SHAT Hematologic Diseases /ID# 250102, Sofia, Not set
Arthur J.E. Child Comprehensive Cancer Centre Pharmacy /ID# 226077, Calgary, Alberta
BC Cancer - Vancouver /ID# 230573, Vancouver, British Columbia
William Osler Health System /ID# 250973, Brampton, Ontario
Juravinski Cancer Centre /ID# 226084, Hamilton, Ontario
Saskatoon Cancer Centre /ID# 226082, Saskatoon, Saskatchewan
The Fifth Medical Center of PLA General Hospital /ID# 230941, Beijing, Beijing
Beijing Cancer Hospital /ID# 229819, Beijing, Beijing
Peking University Third Hospital /ID# 230975, Beijing, Beijing
Fujian Provincial Cancer Hospital /ID# 238430, Fuzhou, Fujian
The First Affiliated Hospital of Xiamen University /ID# 238426, Xiamen, Fujian
Sun Yat-Sen University Cancer Center /ID# 238371, Guangzhou, Guangdong
Guangdong Provincial People's Hospital /ID# 230945, Guangzhou, Guangdong
Nanfang Hospital of Southern Medical University /ID# 238436, Guangzhou, Guangdong
Fourth Hospital of Hebei Medical University /ID# 238656, Shijiazhuang, Hebei
Harbin Medical University Cancer Hospital /Id# 241755, Harbin, Heilongjiang
Henan Cancer Hospital /ID# 230398, Zhengzhou, Henan
Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 234152, Wuhan, Hubei
Hubei Cancer Hospital /ID# 232256, Wuhan, Hubei
The First Affiliated Hospital of Soochow University /ID# 232569, Suzhou, Jiangsu
The Affiliated Hospital of Xuzhou Medical College /ID# 233174, Xuzhou, Jiangsu
The First Affiliated Hospital of Nanchang University /ID# 230399, Nanchang, Jiangxi
Jiangxi Provincial Cancer Hospital /ID# 233379, Nanchang, Jiangxi
The First Hospital of Jilin University /ID# 239618, Changchun, Jilin
The First Hospital of China Medical University /ID# 233201, Shenyang, Liaoning
Shandong Cancer Hospital /ID# 233200, Jinan, Shandong
Fudan University Cancer Hospital /ID# 251516, Shanghai, Shanghai
Shanxi Provincial Cancer Hospital /ID# 250745, Taiyuan, Shanxi
Tianjin Cancer Hospital /ID# 230974, Tianjin, Tianjin
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 259904, Tianjin, Tianjin
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 230387, Hangzhou, Zhejiang
The second affiliated hospital of Zhejiang University school of medicine /ID# 231249, Hangzhou, Zhejiang
Zhejiang Cancer hospital /ID# 231388, Hangzhou, Zhejiang
Clinical Hospital Dubrava /ID# 251809, Zagreb, Grad Zagreb
Klinicka bolnica Merkur /ID# 252481, Zagreb, Grad Zagreb
Klinicki bolnicki centar Zagreb /ID# 250709, Zagreb, Grad Zagreb
Klinicki bolnicki centar Rijeka /ID# 251811, Rijeka, Primorsko-goranska Zupanija
Klinicki Bolnicki Centar (KBC) Split /ID# 250729, Split, Splitsko-dalmatinska Zupanija
Opca bolnica Dr. Josip Bencevic /ID# 251812, Slavonski Brod, Not set
Fakultní Nemocnice Brno - Jihlavská /ID# 225953, Brno, Brno-mesto
Fakultní nemocnice Hradec Králové - Sokolská /ID# 225955, Hradec Králové, Hradec Kralove
Fakultni Nemocnice Ostrava /ID# 225957, Ostrava, Ostrava-mesto
Duplicate_Fakultni Nemocnice v Motole /ID# 225958, Prague, Not set
Fakultni nemocnice Kralovske Vinohrady /ID# 225956, Praha, Not set
Vseobecna fakultni nemocnice v Praze /ID# 225396, Praha, Not set
Rigshospitalet /ID# 226576, Copenhagen Ø, Hovedstaden
Aarhus Universitetshospital - Skejby /ID# 226594, Aarhus, Midtjylland
Roskilde Sygehus /ID# 226597, Roskilde, Sjælland
Odense University Hospital /ID# 226593, Odense, Syddanmark
Sygehus Lillebalt, Vejle /ID# 226592, Vejle, Syddanmark
CHU de Nice - Hôpital Archet 1 /ID# 226127, Nice, Alpes-Maritimes
CHU Clermont-Ferrand /ID# 229283, Clermont, Auvergne-Rhone-Alpes
Institut Paoli-Calmettes /ID# 226557, Marseille, Bouches-du-Rhone
CHU de Rennes - PONTCHAILLOU /ID# 228207, Rennes, Bretagne
CHU Dijon /ID# 238345, Dijon, Cote-d Or
CHU Limoges - Dupuytren 1 /ID# 234235, Limoges CEDEX 1, Franche-Comte
CHU Montpellier - Hopital Saint Eloi /ID# 228191, Montpellier Cedex 5, Herault
Hopital Pitie Salpetriere /ID# 238343, Paris, Ile-de-France
CHU Grenoble - Hopital Michallon /ID# 226128, La Tronche, Isere
CHRU Nancy - Hopitaux de Brabois /ID# 226102, Vandoeuvre-les-Nancy, Meurthe-et-Moselle
CHRU Lille - Hopital Claude Huriez /ID# 226101, Lille, Nord
Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 226560, Creteil, Paris
CHU de Nantes, Hotel Dieu -HME /ID# 226125, Nantes, Pays-de-la-Loire
Centre Hospitalier de la Cote Basque /ID# 249143, Bayonne, Pyrenees-Atlantiques
HCL - Hopital Lyon Sud /ID# 227086, Pierre Benite CEDEX, Rhone
Centre Henri Becquerel /ID# 226103, Rouen, Seine-Maritime
CHU Amiens-Picardie Site Sud /ID# 238347, Amiens CEDEX 1, Somme
CHD Vendée- La Roche-sur-Yon - Les Oudairies /ID# 243899, La Roche Sur Yon, Vendee
CHU Poitiers - La miletrie /ID# 226578, Poitiers, Vienne
Chu Angers /Id# 245931, Angers, Not set
CHU de CAEN - Hopital de la Cote de Nacre /ID# 226582, Caen, Not set
Hôpital Saint-Louis /ID# 226126, Paris, Not set
Institut Curie - site CLCC René Huguenin /ID# 253519, Saint-cloud, Not set
General Hospital of Athens Laiko /ID# 225399, Athens, Attiki
Alexandra General Hospital /ID# 225402, Athens, Attiki
University General Hospital Attikon /ID# 225401, Athens, Attiki
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 225416, Athens, Not set
University General Hospital of Ioannina /ID# 225400, Ioannina, Not set
General University Hospital of Thessaloniki AXEPA /ID# 225398, Thessaloniki, Not set
Theageneio Anticancer Hospital /ID# 225516, Thessaloniki, Not set
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 257189, Gyor, Gyor-Moson-Sopron
Debreceni Egyetem-Klinikai Kozpont /ID# 226821, Debrecen, Hajdu-Bihar
Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 245938, Kaposvár, Somogy
Tolna Varmegyei Balassa Janos Korhaz /ID# 250063, Szekszard, Tolna
Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 226846, Szombathely, Vas
Semmelweis Egyetem /ID# 227239, Budapest, Not set
Orszagos Onkologiai Intezet /ID# 227294, Budapest, Not set
Szegedi Tudományegyetem /ID# 226838, Szeged, Not set
Rambam Health Care Campus /ID# 225981, Haifa, H_efa
Meir Medical Center /ID# 225612, Kfar Saba, HaMerkaz
Assuta Tel Aviv Medical Center /ID# 226066, Tel Aviv, HaMerkaz
The Chaim Sheba Medical Center /ID# 225600, Ramat Gan, Tel-Aviv
Tel Aviv Sourasky Medical Center /ID# 225891, Tel Aviv, Tel-Aviv
Shaare Zedek Medical Center /ID# 259796, Jerusalem, Yerushalayim
Hadassah /ID# 225614, Jerusalem, Yerushalayim
Rabin Medical Center /ID# 225862, Petah Tikva, Not set
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 225551, Bologna, Emilia-Romagna
Fondazione di Religione e di Culto Casa Sollievo della Sofferenza /ID# 225554, San Giovanni Rotondo, Foggia
IRCCS Ospedale San Raffaele /ID# 225555, Milan, Milano
Istituto Europeo Di Oncologia /ID# 225545, Milan, Milano
Azienda Ospedaliera Universitaria Federico II /ID# 225543, Naples, Napoli
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 225775, Torino, Piemonte
Duplicate_Centro di Riferimento Oncologico /ID# 225553, Aviano, Pordenone
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 252192, Meldola, Reggio Emilia
Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 225751, Candiolo, Torino
Azienda Ospedaliero - Universitaria SS. Antonio e Biagio e Cesare Arrigo - Aless /ID# 225542, Alessandria, Not set
I.R.C.C.S Istituto Tumori Giovanni Paolo II /ID# 225548, Bari, Not set
Duplicate_ASST Spedali civili di Brescia /ID# 225549, Brescia, Not set
Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 225773, Novara, Not set
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello /ID# 225541, Palermo, Not set
Azienda Ospedaliero Universitaria Pisana /ID# 225575, Pisa, Not set
Ospedale Santa Maria Delle Croci /ID# 225571, Ravenna, Not set
NHO Nagoya Medical Center /ID# 230677, Nagoya-shi, Aichi
Aichi Cancer Center Hospital /ID# 226090, Nagoya-shi, Aichi
National Cancer Center Hospital East /ID# 250151, Kashiwa-shi, Chiba
Matsuyama Red Cross Hospital /ID# 251068, Matsuyama-shi, Ehime
National Hospital Organization Kyushu Cancer Center /ID# 251622, Fukuoka-shi, Fukuoka
Kyushu University Hospital /ID# 226091, Fukuoka-shi, Fukuoka
Fukushima Medical University Hospital /ID# 250869, Fukushima-shi, Fukushima
Duplicate_Hokkaido University Hospital /ID# 250149, Sapporo-shi, Hokkaido
Kobe City Medical Center General Hospital /ID# 250597, Kobe-shi, Hyogo
University of Tsukuba Hospital /ID# 251282, Tsukuba-shi, Ibaraki
Kanazawa University Hospital /ID# 251770, Kanazawa-shi, Ishikawa
Kagoshima University Hospital /ID# 250163, Kagoshima-shi, Kagoshima
Tokai University Hospital /ID# 251281, Isehara, Kanagawa
Tohoku University Hospital /ID# 250150, Sendai-shi, Miyagi
Okayama University Hospital /ID# 250161, Okayama-shi, Okayama
Kindai University Hospital /ID# 250160, Osakasayama-shi, Osaka
Osaka University Hospital /ID# 251283, Suita-shi, Osaka
National Cancer Center Hospital /ID# 226089, Chuo-ku, Tokyo
The Cancer Institute Hospital Of JFCR /ID# 230269, Koto-ku, Tokyo
Yamagata University Hospital /ID# 230003, Yamagata-shi, Yamagata
Inje University - Busan Paik Hospital /ID# 232262, Busan, Busan Gwang Yeogsi
Seoul National University Bundang Hospital /ID# 225763, Seongnam-si, Gyeonggido
Keimyung University Dongsan Hospital /ID# 232264, Daegu, Gyeongsangbugdo
Dong-A University Medical Center /ID# 228451, Busan, Gyeongsangnamdo
Jeonbuk National University Hospital /ID# 232263, Jeonju, Jeonrabugdo
Seoul National University Hospital /ID# 225760, Seoul, Seoul Teugbyeolsi
Asan Medical Center /ID# 225758, Seoul, Seoul Teugbyeolsi
Samsung Medical Center /ID# 225759, Seoul, Seoul Teugbyeolsi
The Catholic University of Korea, Seoul St. Marys Hospital /ID# 225761, Seoul, Seoul Teugbyeolsi
Ulsan University Hospital /ID# 226971, Ulsan, Ulsan Gwang Yeogsi
Flevo Ziekenhuis /ID# 229606, Almere, Flevoland
Medisch Centrum Leeuwarden /ID# 225605, Leeuwarden, Friesland
Gelre Ziekenhuizen /ID# 229762, Apeldoorn, Gelderland
Canisius-Wilhelmina Ziekenhuis /ID# 231291, Nijmegen, Gelderland
Maastricht Universitair Medisch Centrum /ID# 225607, Maastricht, Limburg
Amphia Ziekenhuis /ID# 229550, Breda, Noord-Brabant
Catharina Ziekenhuis /ID# 230465, Eindhoven, Noord-Brabant
Maxima Medisch Centrum /ID# 225603, Eindhoven, Noord-Brabant
Elisabeth Tweesteden Ziekenhuis /ID# 229773, Tilburg, Noord-Brabant
Noordwest Ziekenhuisgroep /ID# 230613, Alkmaar, Noord-Holland
Vrije Universiteit Medisch Centrum /ID# 225608, Amsterdam, Noord-Holland
Olvg /Id# 229761, Amsterdam, Noord-Holland
Spaarne Gasthuis, Haarlem Zuid /ID# 229621, Haarlem, Noord-Holland
Tergooi /ID# 229772, Hilversum, Noord-Holland
Dijklander Ziekenhuis /ID# 229900, Hoorn Nh, Noord-Holland
Zaans Medisch Centrum /ID# 230614, Zaandam, Noord-Holland
Medisch Spectrum Twente /ID# 225610, Enschede, Overijssel
Meander Medisch Centrum /ID# 229608, Amersfoort, Utrecht
St. Antonius Ziekenhuis /ID# 229901, Nieuwegein, Utrecht
Albert Schweitzer Ziekenhuis /ID# 229560, Dordrecht, Zuid-Holland
Leids Universitair Medisch Centrum /ID# 225606, Leiden, Zuid-Holland
Haaglanden Medisch Centrum /ID# 229686, Den Haag, Not set
Deventer Ziekenhuis /ID# 229937, Deventer, Not set
Universitair Medisch Centrum Groningen /ID# 225602, Groningen, Not set
Jeroen Bosch Ziekenhuis /ID# 229765, S Hertogenbosch, Not set
Diakonessenhuis /ID# 251793, Utrecht, Not set
North Shore Hospital /ID# 250992, Takapuna, Auckland
Christchurch Hospital /ID# 250993, Christchurch, Canterbury
Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka /ID# 228723, Slupsk, Pomorskie
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 225986, Kielce, Swietokrzyskie
Szpital Kliniczny MSWiA z Warminsko-Mazurskim Centrum Onkologii /ID# 225985, Olsztyn, Warminsko-mazurskie
ARS-MEDICAL Sp. z o.o. /ID# 225848, Pila, Wielkopolskie
Centrum Medyczne Pratia Poznan /ID# 227236, Skorzewo, Wielkopolskie
2CA-Braga, Hospital de Braga /ID# 249112, Braga, Not set
IPO Lisboa FG, EPE /ID# 249109, Lisboa, Not set
Unidade Local de Saude de Santa Maria, EPE /ID# 249111, Lisboa, Not set
IPO Porto FG, EPE /ID# 249110, Porto, Not set
Hospital Erasto Gaertner /ID# 262593, Curitiba, Not set
Hematology and Oncology Institute /ID# 230054, Manati, Not set
Pan American Center for Oncology Trials, LLC /ID# 230052, Rio Piedras, Not set
Narodny onkologicky ustav /ID# 238847, Bratislava, Bratislavsky Kraj
Univerzitna nemocnica Martin /ID# 240828, Martin, Zilinsky Kraj
Wits Clinical Research /ID# 227799, Johannesburg, Gauteng
Wits Clinical Research /ID# 227803, Johannesburg, Gauteng
Alberts Cellular Therapy /ID# 227798, Pretoria, Gauteng
University of Cape Town /ID# 227802, Cape Town, Western Cape
Haemalife Inc. /ID# 243391, Kuilsrivier, Western Cape
Instituto Catalan de Oncologia (ICO) Badalona /ID# 228063, Badalona, Barcelona
Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 227393, L'Hospitalet de Llobregat, Barcelona
Hospital Universitario Reina Sofia /ID# 225806, Córdoba, Cordoba
Hospital Clinico Universitario Virgen de la Arrixaca /ID# 255381, El Palmar, Murcia
Clinica Universidad de Navarra - Pamplona /ID# 225809, Pamplona, Navarra
Hospital Parc de Salut del Mar /ID# 225810, Barcelona, Not set
Hospital Universitario Vall d'Hebron /ID# 225811, Barcelona, Not set
Hospital Clinic de Barcelona /ID# 226651, Barcelona, Not set
Hospital Santa Creu i Sant Pau /ID# 225813, Barcelona, Not set
CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 228228, Madrid, Not set
Hospital Universitario Infanta Leonor /ID# 225816, Madrid, Not set
MD Anderson Madrid /ID# 225817, Madrid, Not set
Hospital Universitario Ramon y Cajal /ID# 241750, Madrid, Not set
Hospital Universitario Fundacion Jimenez Diaz /ID# 225804, Madrid, Not set
Hospital Universitario 12 de Octubre /ID# 225815, Madrid, Not set
Hospital Clinico Universitario de Valencia /ID# 225818, Valencia, Not set
Linkoping University Hospital /ID# 233521, Linkoping, Ostergotlands Lan
Skane University Hospital Lund /ID# 227285, Lund, Skane Lan
Karolinska University Hospital Solna /ID# 229284, Solna, Stockholms Lan
Sodra Alvsborgs sjukhus /ID# 228885, Boras, Vastra Gotalands Lan
Sahlgrenska Universitetssjukhuset /ID# 250089, Göteborg, Vastra Gotalands Lan
Kantonsspital Aarau AG /ID# 229112, Aarau, Aargau
Spital Thun /ID# 229499, Thun, Bern
KSW Kantonsspital Winterthur /ID# 241631, Winterthur, Zuerich
Kaohsiung Chang Gung Memorial Hospital /ID# 226670, Kaohsiung City, Kaohsiung
China Medical University Hospital /ID# 226188, Taichung, Not set
Taichung Veterans General Hospital /ID# 226674, Taichung, Not set
National Cheng Kung University Hospital /ID# 226671, Tainan, Not set
Anadolu Saglik Merkezi /ID# 225777, Dilovası, Kocaeli
Ankara Universitesi Fakultesi /ID# 227331, Ankara, Not set
Inonu University Medical Faculty /ID# 226572, Malatya, Not set
Ondokuz Mayis Universitesi /ID# 251247, Samsun, Not set
Karadeniz University /ID# 226573, Trabzon, Not set
Baskent Universitesi Adana Uyg. ve Arast. Merkezi Yuregir Baskent Hastanesi /ID# 225921, Yuregir, Not set
Hammersmith Hospital /ID# 242215, London, England
Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 226692, Norwich, Norfolk
University Hospitals Birmingham NHS Foundation Trust /ID# 229197, Birmingham, Not set
NHS Lothian /ID# 229055, Edinburgh, Not set
Conditions: Diffuse Large B-Cell Lymphoma
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Completed
This is a phase 1B, multi-center, dose-finding study of glofitamab administered in combination with obinutuzumab (Gazyva; \[G\]), rituximab (R) and standard doses of CHOP (G/R-CHOP or R-CHOP) in participants with r/r NHL and G/R CHOP or Pola-R-CHP in participants with untreated diffuse large B-cell lymphoma (DLBCL). Evaluating the safety, preliminary activity, pharmacokinetic (PK), and pharmacodynamic effects of this combination will be the main objectives of this study. The study is divided in... Read More
This is a phase 1B, multi-center, dose-finding study of glofitamab administered in combination with obinutuzumab (Gazyva; \[G\]), rituximab (R) and standard doses of CHOP (G/R-CHOP or R-CHOP) in participants with r/r NHL and G/R CHOP or Pola-R-CHP in participants with untreated diffuse large B-cell lymphoma (DLBCL). Evaluating the safety, preliminary activity, pharmacokinetic (PK), and pharmacodynamic effects of this combination will be the main objectives of this study. The study is divided in two parts:
* Part I: Dose finding in participants with r/r NHL; test use of G vs R in Cycle 1
* Part II: Dose Expansion. The maximum tolerated dose or optimal biological dose (MTD or OBD) will be further assessed in participants with untreated DLBCL (\>18 years of age with an age-adjusted International Prognostic Index (IPI) of 2-5). Glofitamab will be studied in combination with R-CHOP and Pola-R-CHP. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2025
Locations: University of Alabama Medical Center, Birmingham, Alabama +21 locations
University of Alabama Medical Center, Birmingham, Alabama
Levine Cancer Institute, Charlotte, North Carolina
Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania
Peter Maccallum Cancer Centre, Melbourne, Victoria
Princess Margaret Cancer Center, Toronto, Ontario
Rigshospitalet, København Ø, Not set
Hopital Claude Huriez, Lille, Not set
Hopital Hotel Dieu Et Hme, Nantes, Not set
Centre Henri Becquerel, Rouen, Not set
Universitätsklinikum Erlangen, Translational Research Center (TRC), Medizin 5, Erlangen, Not set
Universitätsklinikum Freiburg, Freiburg, Not set
Universitätsklinikum Ulm, Ulm, Not set
Universitätsklinikum Würzburg, Wuerzburg, Not set
Istituto Nazionale Tumori Irccs Fondazione g. Pascale, Napoli, Campania
UO Ematologia, Ospedale S.Maria delle Croci, Ravenna, Emilia-Romagna
Asst Papa Giovanni Xxiii, Bergamo, Lombardia
Istituto Clinico Humanitas, Rozzano, Lombardia
Hospital Universitari Vall d'Hebron, Barcelona, Not set
Hospital Clínic i Provincial, Barcelona, Not set
START Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Not set
University College London Hospitals NHS Foundation Trust, London, Not set
Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, Not set
Conditions: B-Cell Lymphoma, Non-Hodgkin Lymphoma
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Active Not Recruiting
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neurob... Read More
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescents, and young adults with recurrent or refractory Ewing sarcoma (EWS). Read Less
Gender:
ALL
Ages:
Between 2 years and 20 years
Trial Updated:
01/13/2025
Locations: University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama +100 locations
University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama
Phoenix Children's Hospital, Phoenix, Arizona
MemorialCare Health System - Long Beach Medical Center, Long Beach, California
Children's Hospital Los Angeles, Los Angeles, California
Children's Hospital and Research Center at Oakland, Oakland, California
Children's Hospital of Orange County, Orange, California
Lucile Packard Children's Hospital, Palo Alto, California
UCSF Medical Center, San Francisco, California
University of California San Francisco,, San Francisco, California
Children's Hospital Colorado, Aurora, Colorado
Children's National Hospital, Washington, District of Columbia
UF Health Shands Hospital, Gainesville, Florida
University of Florida College of Medicine, Gainesville, Florida
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Johns Hopkins All Children's Outpatient Care Center, Saint Petersburg, Florida
Johns Hopkins All Children's Hospital, Tampa, Florida
Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia
Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia
Children's Healthcare of Atlanta, Medical Office Building, Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Indiana University, Indianapolis, Indiana
Norton Children's Hospital, Louisville, Kentucky
Novak Center for Children's Health, Louisville, Kentucky
Johns Hopkins University, Baltimore, Maryland
University of Michigan Health System, Ann Arbor, Michigan
University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
University of Minnesota, Minneapolis, Minnesota
University of Mississippi Medical Center, Jackson, Mississippi
Children's Mercy Hospital, Kansas City, Missouri
Washington University School of Medicine, Saint Louis, Missouri
Robert Wood Johnson University Hospital, New Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Montefiore Medical Center, Bronx, New York
John R. Oishei Childrens Hospital, Buffalo, New York
Roswell Park Cancer Institute, Buffalo, New York
Cohen Children's Medical Center, New Hyde Park, New York
Morgan Stanley Children's Hospital of New York-Presbyetrian Hospital, New York, New York
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
University Hospitals Cleveland Medical Center, Cleveland, Ohio
Nationwide Children's Hospital, Columbus, Ohio
Cincinnati Children's Liberty Campus, Liberty Township, Ohio
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Oregon Health & Science University, Portland, Oregon
Penn State Children's Hospital and Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania
Buerger Center for Advanced Pediatric Care, Philadelphia, Pennsylvania
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Children's Blood and Cancer Center, Austin, Texas
Dell Children's Medical Center, Austin, Texas
Children's Medical Center Dallas, Dallas, Texas
Cook Children's Medical Center, Fort Worth, Texas
Cook Children's H/O Infusion Center, Grapevine, Texas
Texas Children's Hospital, Houston, Texas
Children's Medical Center Plano, Plano, Texas
Intermountain - Primary Children's Hospital, Salt Lake City, Utah
Primary Children's Hospital Outpatient Services, Salt Lake City, Utah
Children's Hospital of The King's Daughters, Norfolk, Virginia
Children's Hospital of Richmond at VCU, Richmond, Virginia
Seattle Children's Hospital, Seattle, Washington
Children's Wisconsin, Milwaukee, Wisconsin
Medical College of Wisconsin, Milwaukee, Wisconsin
Hospital Pequeno Principe / A ssociacao Hospitalar de Protecao a Infancia, Curitiba, Paraná
Hospital Pequeno Príncipe, Curitiba, Paraná
Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL
Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL
Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, SÃO Paulo
Instituto Nacional de Câncer - INCA, Rio de Janeiro, Not set
Hospital Santa Marcelina, São Paulo, Not set
Alberta Children's Hospital, Calgary, Alberta
Stollery Children's Hospital, Edmonton, Alberta
The Hospital for Sick Children, Toronto, Ontario
CHU Sainte-Justine, Montreal, Quebec
Detska nemocnice FN Brno, Brno, Brno-město
Fakultni nemocnice v Motole, Praha, Praha 5
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Aquitaine
Centre Leon Berard, Lyon, Rhône-alpes
Centre Leon Berard, Lyon, Rhône-alpes
Gustave Roussy, Villejuif, Val-de-marne
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone, Marseille, Not set
Universitätsklinikum Essen, Essen, Nordrhein-westfalen
All India Institute of Medical Sciences, New Delhi, Delhi
Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi
Artemis hospital, Gurugram, Haryana
National Cancer Center, Goyang-si, Kyǒnggi-do
Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul]
Asan Medical Center, Seoul, Seoul-teukbyeolsi [seoul]
Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul]
Instytut Matki i Dziecka, Warsaw, Mazowieckie
Detska fakultna nemocnica s poliklinikou Banska Bystrica, Banska Bystrica, Not set
Narodny ustav detskych chorob, Bratislava, Not set
Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [barcelona]
Hospital Infantil Universitario Niño Jesús, Madrid, Madrid, Comunidad DE
Sahlgrenska Universitetssjukhuset Östra, Gothenburg, Västra Götalands LÄN [se-14]
Ege Universitesi Hastanesi, İzmir, İ̇zmir
Hacettepe Universite Hastaneleri, Ankara, Not set
Royal Victoria Infirmary, Newcastle upon Tyne, England
Royal Hospital for Children, Glasgow, Scotland
Leeds General Infirmary, Leeds, Not set
University College London Hospital, NHS Foundation Trust, London, Not set
Conditions: Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Recruiting
This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019).
The aims of the trial are:
1. To determine the recommended phase II dose (RP2D) of a specific anticancer agent and/or a relevant combination in a pediatric population, to document its tolerability and
2. To explore first signals of activity in a molecularly enriched study p... Read More
This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019).
The aims of the trial are:
1. To determine the recommended phase II dose (RP2D) of a specific anticancer agent and/or a relevant combination in a pediatric population, to document its tolerability and
2. To explore first signals of activity in a molecularly enriched study population. Read Less
Gender:
ALL
Ages:
18 years and below
Trial Updated:
01/08/2025
Locations: Rigshospitalet, Copenhagen, Not set +20 locations
Rigshospitalet, Copenhagen, Not set
Gustave Roussy, Villejuif, Val De Marne
CHU Angers, Angers, Not set
CHU Pellegrin, Bordeaux, Not set
Centre Oscar Lambret, Lille, Not set
Centre Léon Bérard, Lyon, Not set
Hôpital de La Timone, Marseille, Not set
CHU Nantes, Nantes, Not set
Institut Curie, Paris, Not set
Hôpital Armand Trousseau, Paris, Not set
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set
Ospedale Infantile Regina Margherita, Torino, Not set
Prinses Maxima Centrum, Utrecht, Not set
Vall d'Hebron, Barcelona, Not set
Hospital del Nino Jesus, Madrid, Not set
Hospital Universitario La Fe, Valencia, Not set
Birmingham Children's Hospital, Birmingham, Not set
Great Ormond Street Hospital, London, Not set
Royal Manchester Children's Hospital, Manchester, Not set
Royal Victoria Infirmary, Newcastle, Not set
Pediatric and Adolescent Oncology The Royal Marsden Hospital, Sutton, Not set
Conditions: Pediatric Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Active Not Recruiting
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).
After a screening phase of approximately 28 days, each participant will receive neoadjuvant study treatment (Pembrolizumab + Chemotherapy OR Placebo + Chemotherapy) based on the randomization schedule for approximately 24 wee... Read More
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).
After a screening phase of approximately 28 days, each participant will receive neoadjuvant study treatment (Pembrolizumab + Chemotherapy OR Placebo + Chemotherapy) based on the randomization schedule for approximately 24 weeks (8 cycles). Each participant will then undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant study treatment. After definitive surgery, each participant will receive adjuvant study treatment (Pembrolizumab OR Placebo) for approximately 27 weeks (9 cycles). Following adjuvant study treatment, each participant will be monitored for safety, survival and disease recurrence.
The primary study hypothesis is that pembrolizumab is superior to placebo, in combination with chemotherapy, as measured by the rate of Pathological Complete Response (pCR) and/or Event-free Survival (EFS), in participants with locally advanced TNBC. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089), Scottsdale, Arizona +192 locations
Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089), Scottsdale, Arizona
Arizona Oncology Associates PC- HOPE ( Site 8001), Tucson, Arizona
Cedars Sinai Medical Center ( Site 0091), Los Angeles, California
Pacific Cancer Care ( Site 0069), Monterey, California
ICRI ( Site 0072), Whittier, California
University of Colorado Cancer Center ( Site 0021), Aurora, Colorado
Yale University School of Medicine ( Site 0054), New Haven, Connecticut
Christiana Hospital ( Site 0029), Newark, Delaware
Univ of Miami-Sylvester Comprehensive Cancer Center- Kendall satellite ( Site 0079), Miami, Florida
The University of Chicago Medical Center ( Site 0047), Chicago, Illinois
North Shore University Health System ( Site 0081), Evanston, Illinois
Orchard Healthcare Research Inc. ( Site 0049), Skokie, Illinois
Goshen Center for Cancer Care ( Site 0010), Goshen, Indiana
University of Iowa Hospital and Clinics ( Site 0038), Iowa City, Iowa
New England Cancer Specialists ( Site 0005), Scarborough, Maine
Henry Ford Hospital ( Site 0003), Detroit, Michigan
Minnesota Oncology Hematology, PA ( Site 8013), Minneapolis, Minnesota
Rutgers Cancer Institute of New Jersey ( Site 0073), New Brunswick, New Jersey
Broome Oncology, LLC ( Site 8002), Johnson City, New York
Nyack Hospital Infusion Center ( Site 0059), Nyack, New York
TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0044), Cincinnati, Ohio
Oncology Hematology Care, Inc. ( Site 8011), Cincinnati, Ohio
Providence Portland Medical Center ( Site 0052), Portland, Oregon
Northwest Cancer Specialists, P.C. ( Site 8008), Portland, Oregon
Magee - Women's Hospital ( Site 0011), Pittsburgh, Pennsylvania
Rhode Island Hospital ( Site 0060), Providence, Rhode Island
The West Clinic, P.C. ( Site 0078), Germantown, Tennessee
Texas Oncology-Austin Central ( Site 8005), Austin, Texas
Parkland Health and Hospital System ( Site 0093), Dallas, Texas
Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8006), Dallas, Texas
Simmons Cancer Center ( Site 0094), Dallas, Texas
UT Southwestern Medical Center ( Site 0030), Dallas, Texas
Moncrief Cancer Institute ( Site 0092), Fort Worth, Texas
Texas Oncology-Memorial City ( Site 8003), Houston, Texas
Houston Methodist Cancer Center ( Site 0013), Houston, Texas
Texas Oncology- Plano East ( Site 8010), Plano, Texas
Texas Oncology-San Antonio Northeast ( Site 8012), San Antonio, Texas
Texas Oncology-Tyler ( Site 8007), Tyler, Texas
University of Virginia ( Site 0022), Charlottesville, Virginia
Virginia Cancer Specialists, PC ( Site 8009), Fairfax, Virginia
Bon Secours Cancer Institute Medical Oncology at St. Mary's ( Site 0033), Midlothian, Virginia
Peninsula Cancer Institute, LLC ( Site 0041), Newport News, Virginia
Virginia Oncology Associates ( Site 8000), Norfolk, Virginia
Kadlec Clinic Hematology and Oncology ( Site 0087), Kennewick, Washington
Seattle Cancer Care Alliance ( Site 0068), Seattle, Washington
Medical Oncology Associates (Summit Cancer Centers) ( Site 0014), Spokane, Washington
YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 8004), Yakima, Washington
Royal North Shore Hospital ( Site 2000), Sydney, New South Wales
Westmead Hospital ( Site 2002), Sydney, New South Wales
Royal Adelaide Hospital ( Site 2008), Adelaide, South Australia
Cabrini Health ( Site 2009), East Malvern, Victoria
Frankston Hospital ( Site 2010), Franskton, Not set
Royal Brisbane and Women s Hospital ( Site 2003), Herston, Not set
St John of God Subiaco Hospital ( Site 2006), Perth, Not set
Hospital Nossa Senhora da Conceicao ( Site 0203), Porto Alegre, Rio Grande Do Sul
UOPECCAN - Uniao Oeste Paranaense de Estudos e Combate ao Cancer ( Site 0206), Cascavel, Not set
Universidade de Caxias do Sul ( Site 0201), Caxias do Sul, Not set
Hospital Erasto Gaertner ( Site 0207), Curitiba, Not set
Instituto do Cancer do Ceara ( Site 0205), Fortaleza, Not set
Hospital Araujo Jorge ( Site 0204), Goiania, Not set
Hospital Sao Lucas da PUCRS ( Site 0200), Porto Alegre, Not set
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0208), Sao Jose do Rio Preto, Not set
Instituto do Cancer de Sao Paulo - ICESP ( Site 0211), Sao Paulo, Not set
Tom Baker Cancer Centre ( Site 0105), Calgary, Alberta
The Ottawa Hospital - Cancer Care ( Site 0100), Ottawa, Ontario
Princess Margaret Cancer Centre ( Site 0103), Toronto, Ontario
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106), Montreal, Quebec
Jewish General Hospital ( Site 0101), Montreal, Quebec
CIUSSS de l'Estrie-CHUS ( Site 0102), Sherbrooke, Quebec
CHU de Quebec Universite Laval - Hopital du Saint-Sacrement ( Site 0104), Quebec, Not set
Oncomedica S.A. ( Site 0404), Monteria, Cordoba
Oncologos del Occidente S.A. ( Site 0405), Pereira, Risaralda
Hospital Universitario San Ignacio ( Site 0401), Bogota, Not set
Instituto Nacional de Cancerologia [Bogota-Colombia] ( Site 0403), Bogota, Not set
Hemato Oncologos S.A. ( Site 0400), Cali, Not set
Instituto De Cancerologia S.A. ( Site 0406), Medellin, Not set
CHU Jean Minjoz ( Site 0917), Besancon, Not set
Polyclinique Bordeaux Nord Aquitaine ( Site 0911), Bordeaux, Not set
Centre Francois Baclesse ( Site 0907), Caen, Not set
Centre Jean Perrin ( Site 0903), Clermont-Ferrand Cedex 01, Not set
Clinique Victor Hugo ( Site 0901), Le Mans, Not set
Hopital prive du Confluent ( Site 0902), Nantes, Not set
Institut Curie ( Site 0909), Paris, Not set
Hopital Saint Louis ( Site 0908), Paris, Not set
Hopital Diaconesses Croix Saint Simon ( Site 0905), Paris, Not set
CHU de la Miletrie Poitiers ( Site 0913), Poitiers, Not set
Institut Claudius Regaud IUCT Oncopole ( Site 0914), Toulouse Cedex 9, Not set
HELIOS Klinikum Berlin-Buch ( Site 1005), Berlin, Not set
Gynaekologisches Zentrum ( Site 1004), Bonn, Not set
Universitaetsklinikum Erlangen ( Site 1001), Erlangen, Not set
Kliniken Essen Mitte ( Site 1012), Essen, Not set
Universitaetsklinik und Poliklinik Halle/Saale ( Site 1008), Halle, Not set
Universitaetsklinikum Hamburg-Eppendorf ( Site 1007), Hamburg, Not set
Klinikum der Universit. Muenchen ( Site 1002), Muenchen, Not set
Caritasklinik St. Theresia ( Site 1011), Saarbruecken, Not set
Universitaets-Frauenklinik Tuebingen ( Site 1003), Tubingen, Not set
Bon Secours Hospital ( Site 1551), Cork, Not set
St Vincents University Hospital ( Site 1550), Dublin, Not set
Oncology institute ( Site 1601), Beer Sheva, Not set
Assaf Harofeh MC ( Site 1605), Beer Yaakov-Zerifin, Not set
Hadassah Ein Karem - Sharett Institute of Oncology ( Site 1600), Jerusalem, Not set
Rabin-Medical Center ( Site 1604), Petah Tikva, Not set
Sheba Medical Center ( Site 1602), Ramat-Gan, Not set
Sourasky Medical Center ( Site 1603), Tel Aviv, Not set
Istituto Scientifico Romagnolo per Studio e Cura Tumori IRST ( Site 1101), Meldola, FC
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia ( Site 1103), Brescia, Not set
Ospedale San Luca, AZIENDA USL2 TOSCANA NORD OVEST ( Site 1105), Lucca, Not set
Ospedale Civile di Macerata ( Site 1104), Macerata, Not set
Istituto Europeo di Oncologia ( Site 1106), Milano, Not set
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1102), Napoli, Not set
Aichi Cancer Center Hospital ( Site 2502), Nagoya, Aichi
National Cancer Center Hospital East ( Site 2518), Kashiwa, Chiba
National Hospital Organization Hokkaido Cancer Center ( Site 2512), Sapporo, Hokkaido
Hyogo College of Medicine Hospital ( Site 2506), Nishinomiya, Hyogo
Tokai University Hospital ( Site 2517), Isehara, Kanagawa
St. Marianna University School of Medicine Hospital ( Site 2516), Kawasaki, Kanagawa
Kindai University Hospital ( Site 2507), Osakasayama, Osaka
Saitama Medical University International Medical Center ( Site 2513), Hidaka, Saitama
Saitama Cancer Center ( Site 2510), Kitaadachi-gun, Saitama
Shizuoka Cancer Center Hospital and Research Institute ( Site 2514), Sunto-gun, Shizuoka
Chiba Cancer Center ( Site 2519), Chiba, Not set
Hiroshima City Hiroshima Citizens Hospital ( Site 2501), Hiroshima, Not set
Social medical corporation Hakuaikai Sagara Hospital ( Site 2508), Kagoshima, Not set
Kumamoto University Hospital ( Site 2515), Kumamoto, Not set
National Hospital Organization Osaka National Hospital ( Site 2505), Osaka, Not set
National Cancer Center Hospital ( Site 2500), Tokyo, Not set
St.Luke's International Hospital ( Site 2511), Tokyo, Not set
Toranomon Hospital ( Site 2503), Tokyo, Not set
The Cancer Institute Hospital of JFCR ( Site 2509), Tokyo, Not set
Seoul National University Hospital ( Site 2101), Seoul, Not set
Severance Hospital Yonsei University Health System ( Site 2100), Seoul, Not set
Asan Medical Center ( Site 2102), Seoul, Not set
Samsung Medical Center ( Site 2103), Seoul, Not set
Mazowiecki Szpital Onkologiczny ( Site 1713), Wieliszew, Mazowieckie
Centrum Onkologii Instytut im. Marii Skłodowskiej Curie ( Site 1717), Gliwice, Slaskie
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1708), Bydgoszcz, Not set
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1712), Bydgoszcz, Not set
Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1701), Gdynia, Not set
Centrum Onkologii Instytut im. Marii Sklodowskiej Curie ( Site 1719), Krakow, Not set
Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli ( Site 1700), Lublin, Not set
Dolnoslaskie Centrum Onkologii. ( Site 1702), Wroclaw, Not set
Fundacao Champalimaud ( Site 2444), Lisboa, Not set
Hospital de Santa Maria, E.P.E. ( Site 2445), Lisboa, Not set
Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2446), Porto, Not set
Arkhangelsk Clinical Oncological Dispensary ( Site 1810), Arkhangelsk, Not set
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1805), Chelyabinsk, Not set
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1806), Kazan, Not set
Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 1801), Moscow, Not set
GBU RO Regional Clinical Oncological Dispensary ( Site 1808), Ryazan, Not set
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1803), Saint Petersburg, Not set
Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1804), Ufa, Not set
National Cancer Centre Singapore ( Site 2600), Singapore, Not set
ICO L Hospitalet ( Site 1305), Hospitalet de Llobregat, Barcelona
Hospital Quiron de Madrid ( Site 1303), Pozuelo de Alarcon, Madrid
Hospital del Mar ( Site 1306), Barcelona, Not set
Instituto Oncologico Baselga.Hospital Quiron. ( Site 1312), Barcelona, Not set
Hospital General Universitari Vall d Hebron ( Site 1301), Barcelona, Not set
Hospital Universitario Reina Sofia ( Site 1304), Cordoba, Not set
Hospital Universitario Ramon y Cajal ( Site 1300), Madrid, Not set
Complejo Hospitalario Universitario de Santiago ( Site 1308), Santiago de Compostela, Not set
Hospital Universitario Virgen del Rocio ( Site 1314), Sevilla, Not set
Hospital Clinico Univ de Valencia ( Site 1313), Valencia, Not set
Linkopings Universitetssjukhus ( Site 1402), Linkoping, Not set
Karolinska Universitetssjukhuset Solna ( Site 1404), Solna, Not set
Norrlands Universitetssjukhus ( Site 1401), Umea, Not set
Akademiska Sjukhuset ( Site 1403), Uppsala, Not set
Taipei Veterans General Hospital ( Site 2302), Taipei, Beitou
National Cheng Kung University Hospital ( Site 2305), Tainan, Not set
National Taiwan University Hospital ( Site 2301), Taipei, Not set
MacKay Memorial Hospital ( Site 2303), Taipei, Not set
Koo Foundation Sun Yat-Sen Cancer Center ( Site 2304), Taipei, Not set
Linkou Chang Gung Memorial Hospital ( Site 2300), Taoyuan, Not set
Samsun Ondokuz Mayıs Universitesi Tıp Fakultesi Hastanesi ( Site 1910), Samsun, Atakum
Adana Acıbadem Hospital Department of Medical Oncology ( Site 1906), Adana, Not set
Baskent Unıversity Adana Kısla Hospital ( Site 1903), Adana, Not set
Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1912), Ankara, Not set
Abdurrahman Yurtaslan Oncology Training and Research Hospital ( Site 1909), Ankara, Not set
Ozel Medicana International Ankara Hastanesi ( Site 1915), Ankara, Not set
Antalya Memorial Hospital Department of Medical Oncology ( Site 1908), Antalya, Not set
Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1901), Edirne, Not set
Acibadem Altunizade Hastanesi ( Site 1900), Istambul, Not set
İstanbul University Cerrahpaşa Medical Faculty ( Site 1904), Istanbul, Not set
Amerikan Hospital Medical ( Site 1902), Istanbul, Not set
Memorial Sisli Hastanesi ( Site 1913), Istanbul, Not set
Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 1905), Izmir, Not set
Izmir Medical Park Hospital Department of Medical Oncology ( Site 1907), Izmir, Not set
Colchester General Hospital ( Site 1508), Colchester, Essex
Barts Cancer Institute ( Site 1500), London, Not set
St George s Hospital ( Site 1516), London, Not set
Maidstone Hospital ( Site 1511), Maidstone, Not set
The James Cook University Hospital ( Site 1515), Middlesbrough, Not set
Nottingham University Hospitals NHS Trust ( Site 1505), Nottingham, Not set
Royal Cornwall Hospitals NHS Trust ( Site 1504), Truro, Not set
Conditions: Triple Negative Breast Neoplasms
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Terminated
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with chemotherapy or venetoclax, in pediatric and young adult participants with acute leukemias or solid tumors.
This study is divided into three parts: Part 1 will begin with dose escalation of idasanutlin as a single agent in pediatric participants with relapsed or refractory so... Read More
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with chemotherapy or venetoclax, in pediatric and young adult participants with acute leukemias or solid tumors.
This study is divided into three parts: Part 1 will begin with dose escalation of idasanutlin as a single agent in pediatric participants with relapsed or refractory solid tumors to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and to characterize dose-limiting toxicities (DLTs). Following MTD/MAD identification, three separate safety run-in cohorts in neuroblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) will be conducted to identify the recommended Phase 2 dose (RP2D) of idasanutlin in each combination, with chemotherapy or venetoclax. Part 2 will evaluate the safety and early efficacy of idasanutlin in combination with chemotherapy or venetoclax in newly enrolled pediatric and young adult participants in neuroblastoma, AML,and ALL cohorts at idasanutlin RP2D. Part 3 will potentially be conducted as an additional expansion phase of the idasanutlin combination cohorts in neuroblastoma, AML, or ALL for further response and safety assessment. Read Less
Gender:
ALL
Ages:
Between 0 years and 30 years
Trial Updated:
12/18/2024
Locations: Arkansas Children's Hospital Research Institute, Little Rock, Arkansas +13 locations
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas
Lucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California
Arnold Palmer Hosp-Children, Orlando, Florida
Memorial Sloan Kettering Cancer Center, New York, New York
University of Texas Health Science Center at San Antonio, San Antonio, Texas
Alberta Children'S Hospital, Calgary, Alberta
Centre Leon Berard, Lyon CEDEX 08, Not set
Institut Curie, Paris, Not set
Prinses Maxima Centrum, Utrecht, Not set
Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona
Hospital Infantil Universitario Nino Jesus, Madrid, Not set
Birmingham Children's Hospital, Birmingham, Not set
The Royal Victoria Infirmary; Paediatric and Adolescent Oncology Unit, Newcastle Upon Tyne, Not set
Royal Marsden Hospital; Pediatric Unit, Surrey, Not set
Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Completed
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer.
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Local Institution - 0136, Mobile, Alabama +239 locations
Local Institution - 0136, Mobile, Alabama
Local Institution - 0052, Greenbrae, California
Local Institution - 0051, Whittier, California
Local Institution - 0182, Stamford, Connecticut
Local Institution - 0150, Jacksonville, Florida
Local Institution - 0097, Miami, Florida
Local Institution - 0149, Pensacola, Florida
Local Institution - 0120, Tallahassee, Florida
Local Institution - 0054, Athens, Georgia
Local Institution - 0107, Atlanta, Georgia
Local Institution - 0056, Columbus, Georgia
Local Institution - 0221, Chicago, Illinois
Local Institution - 0227, Fort Wayne, Indiana
Local Institution - 0222, Topsham, Maine
Local Institution - 0146, Bethesda, Maryland
HCA Midwest Division, Kansas City, Missouri
Local Institution - 0109, Florham Park, New Jersey
Local Institution - 0050, Hackensack, New Jersey
Local Institution - 0180, New Brunswick, New Jersey
Local Institution - 0181, Albuquerque, New Mexico
Local Institution - 0041, Bronx, New York
Local Institution - 0283, Charlotte, North Carolina
Duke Cancer Institute, Durham, North Carolina
Local Institution - 0053, Cleveland, Ohio
Local Institution - 0218, Nashville, Tennessee
Local Institution - 0121, Fort Worth, Texas
Local Institution - 0224, Fairfax, Virginia
Local Institution - 0122, Fredericksburg, Virginia
Virginia Cancer Institute, Richmond, Virginia
Local Institution - 0274, Seattle, Washington
Local Institution - 0012, Ciudad Autonoma Beunos Aires, Buenos Aires
Local Institution - 0015, La Plata, Buenos Aires
Local Institution - 0020, Buenos Aires, Ciudad Autónoma De Buenos Aires
Local Institution - 0294, Córdoba, Cordoba
Local Institution - 0303, Río Cuarto, Cordoba
Local Institution - 0011, Caba, Distrito Federal
Local Institution - 0008, Capital Federal, Distrito Federal
Local Institution - 0013, Ciudad Autonoma de Buenos Aires, Distrito Federal
Local Institution - 0014, Rosario Santa Fe, Santa FE
Local Institution - 0021, Cordoba, Not set
Local Institution, La Rioja, Not set
Local Institution, Viedma, Not set
Local Institution - 0071, North Sydney, New South Wales
Local Institution - 0069, Port Macquarie, New South Wales
Local Institution - 0072, Herston, Queensland
Local Institution - 0067, Elizabeth Vale, South Australia
Local Institution - 0066, Clayton, Victoria
Local Institution - 0142, Clayton, Victoria
Local Institution - 0070, Melbourne, Victoria
Local Institution - 0068, North Ballarat, Victoria
Local Institution - 0045, Graz, Not set
Local Institution - 0042, Innsbruck, Not set
Local Institution - 0048, Salzburg, Not set
Local Institution - 0046, Wien, Not set
Local Institution - 0047, Wien, Not set
Local Institution - 0187, Brussels, Not set
Local Institution - 0030, Charleroi, Not set
Local Institution - 0037, Edegem, Not set
Local Institution - 0032, Gent, Not set
Local Institution - 0031, Liege, Not set
Local Institution - 0130, Fortaleza, Ceara
Local Institution - 0225, Brasilia, Distrito Federal
Local Institution - 0287, Goiânia, Goias
Local Institution - 0133, Belo Horizonte, Minas Gerais
Local Institution - 0132, Ijui, RIO Grande DO SUL
Local Institution - 0288, Porto Alegre, RIO Grande DO SUL
Local Institution - 0131, Porto Alegre, Rio Grande Do Sul
Local Institution - 0135, Porto Alegre, RIO Grande DO SUL
Local Institution - 0273, Santa Cruz do Sul, Rio Grande Do Sul
Local Institution - 0134, Barretos, SAO Paulo
Local Institution - 0272, São Paulo, SAO Paulo
Local Institution - 0128, Santo André, São Paulo
Local Institution - 0129, Rio de Janeiro, Not set
Local Institution - 0144, São Paulo, Not set
Local Institution - 0104, São Paulo, Not set
Local Institution - 0194, Montreal, Quebec
Local Institution - 0095, Montréal, Quebec
Local Institution - 0058, Sherbrooke, Quebec
Local Institution - 0197, La Serena, Coquimbo
Local Institution - 0016, Santiago de Chile, Metropolitana
Local Institution - 0019, Santiago Region Metropolitana, Metropolitana
Local Institution - 0318, Santiago, Metropolitana
Local Institution - 0018, Vina del Mar, Valparaiso
Local Institution - 0326, Antofagasta, Not set
Local Institution - 0235, Bengbu, Anhui
Local Institution - 0239, Hefei, Anhui
Local Institution, Beijing, Beijing
Local Institution - 0319, Chongqing, Chongqing
Local Institution - 0232, Chongqing, Chongqing
Local Institution - 0267, Guangzhou, Guangdong
Local Institution - 0241, Guangzhou, Guangdong
Local Institution, Guangzhou, Guangdong
Local Institution - 0312, Zunyi, Guizhou
Local Institution - 0240, Shjiazhuang, Hebei
Local Institution - 0250, Wuhan, Hebei
Local Institution - 0248, Harbin, Heilongjiang
Local Institution, Zhengzhou, Henan
Local Institution - 0255, Changchun, Jilin
Local Institution - 0247, Changchun, Jilin
Local Institution - 0252, Shenyang, Liaoning
Local Institution - 0263, Xian, Shan3xi
Local Institution - 0245, Jinan, Shandong
Local Institution - 0256, Qingdao, Shandong
Local Institution - 0214, YanTai, Shandong
Local Institution - 0127, Shanghai, Shanghai
Local Institution - 0244, Chengdu, Sichuan
Local Institution - 0254, Tianjin, Tianjin
Local Institution - 0311, Urumqi, Xinjiang
Local Institution - 0238, Hangzhou, Zhejiang
Local Institution - 0231, Hangzhou, Zhejiang
Local Institution - 0237, Hangzhou, Zhejiang
Local Institution - 0215, Beijing, Not set
Local Institution - 0261, Barranquilla, Atlántico
Local Institution - 0203, Colombia, Bogota
Local Institution - 0113, Montería, Córdoba
Local Institution - 0094, Bogotá, Distrito Capital De Bogotá
Local Institution - 0098, Piedecuesta, Santander
Local Institution - 0093, Cali, Not set
Local Institution - 0271, Pereira, Not set
Local Institution - 0202, Rionegro, Not set
Local Institution - 0100, Hradec Kralove, Not set
Local Institution - 0103, Novy Jicin, Not set
Local Institution - 0101, Olomouc, Not set
Local Institution - 0099, Praha 10, Not set
Local Institution - 0167, Aarhus N, Midtjylland
Local Institution - 0165, Herlev, Not set
Local Institution - 0164, Kobenhavn O, Not set
Local Institution - 0166, Naestved, Not set
Local Institution - 0001, Helsinki, Not set
Local Institution - 0160, Tampere, Not set
Local Institution - 0216, Le Mans, Sarthe
Local Institution - 0004, Besancon, Not set
Local Institution - 0024, Brest, Not set
Local Institution - 0162, Clermont-Ferrand, Not set
Local Institution - 0153, Lyon, Not set
Local Institution - 0152, Montpellier, Not set
Local Institution - 0161, Paris, Not set
Local Institution - 0195, Plerin, Not set
Local Institution - 0002, Saint Herblain, Not set
Local Institution - 0258, Strasbourg, Not set
Local Institution - 0228, Toulon Cedex, Not set
Local Institution - 0003, Villejuif, Not set
Local Institution - 0084, München, Bayern
Local Institution - 0079, Saarbruecken, Saarland
Local Institution - 0083, Berlin, Not set
Local Institution - 0112, Dresden, Not set
Local Institution - 0081, Essen, Not set
Local Institution - 0158, Frankfurt, Not set
Local Institution - 0223, Hamburg, Not set
Local Institution - 0087, Heidelberg, Not set
Local Institution - 0089, Homburg, Not set
Local Institution - 0080, Köln, Not set
Local Institution - 0196, Leipzig, Not set
Local Institution - 0111, Moenchengladbach, Not set
Local Institution - 0156, Rostock, Not set
Local Institution - 0157, Velbert, Not set
Local Institution - 0105, Würzburg, Not set
Local Institution - 0115, Hong Kong, Not set
Local Institution - 0034, Dublin 8, Dublin
Local Institution - 0035, Beaumont, Not set
Local Institution - 0036, Cork, Not set
Local Institution - 0191, Catanzaro, Not set
Local Institution - 0207, Milano, Not set
Azienda Ospedaliero Universitaria Federico II di Napoli, Napoli, Not set
Local Institution - 0124, Napoli, Not set
Local Institution - 0155, Padova, Not set
Fondazione Irccs - Policlinico San Matteo, Pavia, Not set
Local Institution - 0190, Roma, Not set
Local Institution - 0125, Rozzano (MI), Not set
Local Institution - 0325, Seongnam, Not set
Local Institution - 0295, Seoul, Not set
Local Institution - 0320, Seoul, Not set
Local Institution - 0290, Seoul, Not set
Local Institution - 0291, Seoul, Not set
Local Institution - 0262, Tijuana, BAJA California
Local Institution - 0168, Mexico City, Distrito Federal
Local Institution - 0154, Mexico City, Distrito Federal
Local Institution - 0330, Zapopan, Jalisco
Local Institution - 0137, Monterrey, Nuevo LEON
Local Institution - 0212, Merida, Yucatán
Local Institution - 0280, Campeche, Not set
Local Institution - 0091, Chihuahua, Not set
Local Institution - 0145, Colima, Not set
Local Institution - 0141, Oaxaca, Not set
Local Institution - 0033, Amsterdam, Not set
Local Institution - 0177, Breda, Not set
Local Institution - 0199, Deventer, Not set
Local Institution - 0147, Utrecht, Not set
Local Institution - 0335, Bydgoszcz, Not set
Local Institution - 0061, Koszalin, Not set
Local Institution - 0059, Krakow, Not set
Local Institution - 0063, Lodz, Not set
Local Institution - 0062, Opole, Not set
Local Institution - 0060, Warszawa, Not set
Local Institution - 0334, Gliwice, Śląskie
Local Institution - 0210, Lisboa, Not set
Local Institution - 0211, Lisboa, Not set
Local Institution - 0209, Porto, Not set
Local Institution - 0110, Ponce, Not set
Local Institution - 0029, Bucharest, Not set
Local Institution - 0270, Bucharest, Not set
Local Institution - 0025, Bucuresti, Not set
Local Institution - 0028, Craiova, Not set
Local Institution - 0027, Floresti, Not set
Local Institution - 0026, Suceava, Not set
Local Institution, Krasnodar, Not set
Local Institution - 0119, Moscow, Not set
Local Institution, Moscow, Not set
Local Institution - 0285, Moskva, Not set
Local Institution, Ryazan, Not set
Local Institution - 0284, Saint Petersburg, Not set
Local Institution - 0306, Sankt-Peterburg, Not set
Local Institution, Sochi, Not set
Local Institution - 0078, Singapore, Not set
Local Institution - 0076, Singapore, Not set
Local Institution - 0077, Singapore, Not set
Local Institution - 0205, Elche, Alicante
Local Institution - 0171, Barcelona, Not set
Local Institution - 0172, Barcelona, Not set
Local Institution - 0173, Madrid, Not set
Local Institution - 0176, Madrid, Not set
Local Institution - 0169, Malaga, Not set
Local Institution - 0204, Pamplona, Not set
Local Institution - 0174, Santiago de Compostela, Not set
Local Institution - 0170, Sevilla, Not set
Local Institution - 0175, Valencia, Not set
Local Institution - 0184, Basel, Not set
Local Institution - 0186, Lausanne, Not set
Local Institution - 0185, Thun, Not set
Local Institution - 0301, Kaohsiung, Not set
Local Institution - 0300, Tainan City, Not set
Local Institution - 0298, Tainan, Not set
Local Institution - 0305, Taipei, Not set
Local Institution - 0297, Taipei, Not set
Local Institution - 0073, Adana, Not set
Local Institution - 0257, Ankara, Not set
Local Institution - 0075, Antalya, Not set
Local Institution - 0074, Istanbul, Not set
Local Institution - 0006, Withington, Manchester
Local Institution - 0005, London, Not set
Conditions: Breast Cancer
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Completed
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +71 locations
Banner MD Anderson Cancer Center, Gilbert, Arizona
Mayo Clinic Hospital, Phoenix, Arizona
UC San Diego Moores Cancer Center, La Jolla, California
UCLA, Santa Monica, California
Stanford Cancer Institute, Stanford, California
University of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center, Miami, Florida
Moffitt Cancer Center, Tampa, Florida
Northwestern University, Chicago, Illinois
University of Chicago Medical Center, Chicago, Illinois
University of Iowa Hospitals and Clinincs, Iowa City, Iowa
The University of Kansas Cancer Center, Kansas City, Kansas
University of Maryland, Greenbaum Comprehensive Cancer Center, Baltimore, Maryland
Dana-Farber Cancer Institute, Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Mayo Clinic, Patient Location, Rochester, Minnesota
Washington University School of Medicine, Saint Louis, Missouri
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center, New York, New York
Icahn School of Medicine at Mount Sinai, New York, New York
University of Rochester Medical Center, Rochester, New York
Cleveland Clinic, Cleveland, Ohio
James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Thomas Jefferson University, Philadelphia, Pennsylvania
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Sarah Cannon Research Institute, Nashville, Tennessee
Henry-Joyce Cancer Center, Nashville, Tennessee
The University of Texas, MD Anderson Cancer Center, Houston, Texas
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah
University of Virginia Health System, Charlottesville, Virginia
Swedish Cancer Institute, Seattle, Washington
Peter MacCallum Cancer Center, Melbourne, Victoria
Universitatsklinikum Graz, Division of Hematology, Graz, Not set
Medizinische Universitat Innsbruck, Innere Medizin V - Hamatologie und Onkologie, Innsbruck, Not set
Cliniques Universiaires Saint-Luc, Brussels, Not set
UZ Gasthuisberg, Leuven, Not set
Vancouver General Hospital, Vancouver, British Columbia
CancerCare Manitoba, Winnipeg, Manitoba
Uninversity Health Network - Princess Margaret Cancer Center, Toronto, Ontario
McGill University Health Center, Montreal, Quebec
QEII Health Sciences Centre, Halifax, Not set
Centre Integre Universitaire de Sante et Services Sociaux de l'Est-de-l'lle-de-Montreal / Hopital Maisonneuve-Rosemont, Montréal, Not set
The Ottawa Hospital - General Campus, Ottawa, Not set
CHU de Quebec-Universite Laval, Hopital de L'Enfante-Jesus, Québec, Not set
CHRU de Lille - Hopital Claude Huriez, Lille cedex, Not set
Hopital Saint-Louis, Paris, Not set
Centre Hospitalier Lyon-Sud - Service d'Hematologie clinique, Pierre Benite, Not set
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou, Rennes, Not set
Universitäts-klinikum Dresden, Dresden, Not set
Universitatsmedizin Gottingen, Göttingen, Not set
Universitatsklinikum Hamburg-Eppendorf, Hamburg, Not set
Universitätsklinikum Heidelberg, Heidelberg, Not set
Universitäts-klinikum Würzburg, Würzburg, Not set
Tel Aviv Sourasky Medical Center, Tel Aviv, Not set
Instituto di Ematologia "L. e A. Seragnoli" - Dipartimento di Medicina Specialistica Diagnostica e Sperimentale, Bologna, Not set
IRCCS Ospedale San Raffaele di Milano, Milano, Not set
Academic Medical Center, Amsterdam, Not set
University Medical Center Groningen, Groningen, Not set
Erasmus Medical Center, Rotterdam, Not set
University Medical Center Utrecht, Utrecht, Not set
Hospital Clinic de Barcelona, Barcelona, Not set
Institut Catala d'Oncologia, Barcelona, Not set
Hospital Universitario La Paz, Madrid, Not set
Clinica Universidad de Navarra, Pamplona, Not set
Hospital Universitario de Salamanca, Salamanca, Not set
Uppsala Akademiska Sjukhus, Uppsala, Not set
IOSI, OSpedale Regionale Bellinzona e Valli, Bellinzona, Not set
University Hospital Zurich, Zürich, Not set
University Hospitals Birmingham NHS Foundation Trust, Birmingham, Not set
Barts Health NHS Trust, London, Not set
University College London Hospitals NHS Foundation Trust, London, Not set
The Christie NHS Foundation Trust, Manchester, Not set
The Royal Marsden NHS Foundation Trust, Sutton, Not set
Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
49 - 60 of 244
